Latest period
-$28.2M
YoY change
-19.8%
5Y CAGR
—
Peak year (FY2006)
-$2.11M
Latest annual
-$28.4M
Free Cash Flow history chart for SELLAS Life Sciences Group (SLS) from 2016 to 2025
Latest: -$28.4M
Free Cash Flow growth chart for SELLAS Life Sciences Group (SLS) from 2016 to 2025
Latest: -19.8%
Free Cash Flow history table for SELLAS Life Sciences Group (SLS) from 2006 to 2025
| FY2025 | -$28.4M | -19.8% | +$7.01M | ||
| FY2024 | -$35.4M | -4.1% | +$1.51M | ||
| FY2023 | -$36.9M | +30.4% | -$8.6M | ||
| FY2022 | -$28.3M | +8.8% | -$2.29M | ||
| FY2021 | -$26M | +149.8% | -$15.6M | ||
| FY2020 | -$10.4M | -41.0% | +$7.23M | ||
| FY2019 | -$17.6M | -42.0% | +$12.8M | ||
| FY2018 | -$30.4M | +176.8% | -$19.4M | ||
| FY2017 | -$11M | -75.5% | +$33.9M | ||
| FY2016 | -$44.9M | -7.0% | +$3.39M | ||
| FY2015 | -$48.3M | -0.2% | +$84K | ||
| FY2014 | -$48.4M | +8.1% | -$3.64M | ||
| FY2013 | -$44.8M | +113.5% | -$23.8M | ||
| FY2012 | -$21M | +42.4% | -$6.24M | ||
| FY2011 | -$14.7M | +42.1% | -$4.36M | ||
| FY2010 | -$10.4M | -12.6% | +$1.49M | ||
| FY2009 | -$11.9M | +23.5% | -$2.26M | ||
| FY2008 | -$9.6M | +52.9% | -$3.32M | ||
| FY2007 | -$6.28M | +197.2% | -$4.16M | ||
| FY2006 | -$2.11M | — | — |
- FY2025-$28.4M-19.8%
- FY2024-$35.4M-4.1%
- FY2023-$36.9M+30.4%
- FY2022-$28.3M+8.8%
- FY2021-$26M+149.8%
- FY2020-$10.4M-41.0%
- FY2019-$17.6M-42.0%
- FY2018-$30.4M+176.8%
- FY2017-$11M-75.5%
- FY2016-$44.9M-7.0%
- FY2015-$48.3M-0.2%
- FY2014-$48.4M+8.1%
- FY2013-$44.8M+113.5%
- FY2012-$21M+42.4%
- FY2011-$14.7M+42.1%
- FY2010-$10.4M-12.6%
- FY2009-$11.9M+23.5%
- FY2008-$9.6M+52.9%
- FY2007-$6.28M+197.2%
- FY2006-$2.11M—
Free Cash Flow values are taken from SELLAS Life Sciences Group's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Free Cash Flow at SELLAS Life Sciences Group (SLS)
Free Cash Flow for SELLAS Life Sciences Group (SLS): headline value -$28.2M · YoY -19.8%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
SELLAS Life Sciences Group (SLS) most recent annual free cash flow stands at -$28.4M (2025) – declined 19.8% year-over-year.
2006 marks the peak free cash flow at -$2.11M, with the historical low of -$48.4M recorded in 2014.
SELLAS Life Sciences Group Free Cash Flow by Year
SELLAS Life Sciences Group Free Cash Flow 2025: -$28.4M
SELLAS Life Sciences Group posted free cash flow of -$28.4M in 2025, declined 19.8% below 2024.
SELLAS Life Sciences Group Free Cash Flow 2024: -$35.4M
In 2024, SELLAS Life Sciences Group reported free cash flow of -$35.4M, edged down 4.1% below 2023.
SELLAS Life Sciences Group Free Cash Flow 2023: -$36.9M
SELLAS Life Sciences Group free cash flow in 2023 was -$36.9M, surged 30.4% from 2022.
SELLAS Life Sciences Group Free Cash Flow 2022: -$28.3M
2022's free cash flow for SELLAS Life Sciences Group came in at -$28.3M, grew 8.8% from 2021.
SELLAS Life Sciences Group Free Cash Flow 2021: -$26M
SELLAS Life Sciences Group free cash flow in 2021 was -$26M.
See more financial history for SELLAS Life Sciences Group (SLS).
Sector peers by Free Cash Flow
Healthcare peers of SELLAS Life Sciences Group (SLS), ranked by their latest free cash flow
| $19.7B | |
| $17.8B | |
| $16.1B | |
| $12.4B | |
| $8.97B | |
| $8.1B | |
| $6.29B | |
| $4.52B |
- $19.7B
- $17.8B
- $16.1B
- $12.4B
- $8.97B
- $8.1B
- $4.52B
Frequently asked questions
SELLAS Life Sciences Group (SLS) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.